Copy to clipboard 
Lincotek and Promimic announced a strategic license agreement that expands Lincotek’s capabilities by adding Promimic’s HAnano Surface technology into its service portfolio.
The new arrangement further strengthens the partnership between the two companies, building upon the existing joint venture – Nano Processing Inc. (NPI) – between Promimic and Danco Medical, a Lincotek company. NPI has responsibility for processing of implants with HAnano Surface within the U.S. market.
The move will allow Lincotek to offer the HAnano Surface technology to its customers directly, and enhance its position as a leader in the medical device industry. HAnano Surface is an advanced super-hydrophilic and bioactive surface treatment for orthopedic implants that improves osseointegration of medical devices through its biomimicking nanometerthin hydroxyapatite (HA) crystals. This surface treatment provides superior biocompatibility, enhanced early stability, faster healing and long-term implant success.
For Promimic, the agreement provides an expanded reach into the global orthopedic market, and enables them to offer their customers access to enhanced processing capabilities beyond surface treatments
“The new strategic licensing agreement provides a perfect match for both companies”, said Magnus Larsson, CEO of Promimic. “Lincotek’s extensive experience and capabilities in the 3D printing of implants, combined with our innovative surface treatment, will enable us to modify complex geometries uniformly, including microporous structures and their internal surfaces. Adding the super hydrophilic properties of HAnano Surface to the implant, without clogging the pores, promotes faster and better ongrowth, as well as in-growth of bone directly to the implant surface.”
Andrea Colombo CEO of Lincotek, commented: “We are excited to further strengthen the strategic partnership between Lincotek and Promimic. With this partnership our customers will have easier and better access to the full potential of the HAnano Surface technology, which will play a vital role in advancing implant technology for modern medical applications, ensuring implants are even better-performing and longer-lasting. Through this strengthened partnership, Lincotek and Promimic reaffirm their commitment to innovation in the medical industry, delivering next-generation solutions that improve patient outcomes and set new standards in implant surface technology.”
While this strategic partnership is initially focused on the U.S. market, the agreement is worldwide in nature, which allows the two companies to grow together globally as new opportunities arise.
Source: Lincotek Medical
